- Home
- PSTV
as 01-22-2025 4:00pm EST
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).
| Founded: | 1996 | Country: | United States |
| Employees: | N/A | City: | AUSTIN |
| Market Cap: | 6.3M | IPO Year: | N/A |
| Target Price: | $13.50 | AVG Volume (30 days): | 34.6K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.09 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.93 - $2.67 | Next Earning Date: | 03-04-2025 |
| Revenue: | $5,725,000 | Revenue Growth: | 52.63% |
| Revenue Growth (this year): | 32.12% | Revenue Growth (next year): | -24.60% |
Latest PLUS THERAPEUTICS Inc. News
PSTV Breaking Stock News: Dive into PSTV Ticker-Specific Updates for Smart Investing
GlobeNewswire
a month ago
Plus Therapeutics Presents Positive ReSPECT-LM Phase 1 Interim Data for Breast Cancer Patients with Leptomeningeal Metastases at the 2024 San Antonio Breast Cancer Symposium
Argus Research
a month ago
Daily – Vickers Top Insider Picks for 12/10/2024
Argus Research
a month ago
Daily – Vickers Top Insider Picks for 12/09/2024
Argus Research
2 months ago
Daily – Vickers Top Insider Picks for 12/06/2024
Argus Research
2 months ago
Daily – Vickers Top Insider Picks for 12/05/2024
GlobeNewswire
2 months ago
Plus Therapeutics to Showcase ReSPECT-LM Phase 1 Interim Data for Leptomeningeal Metastases at the 2024 San Antonio Breast Cancer Symposium
Argus Research
2 months ago
Daily – Vickers Top Insider Picks for 12/04/2024
GlobeNewswire
2 months ago
Plus Therapeutics Expands Strategic Agreement with Telix IsoTherapeutics Group for Rhenium-186 Radioisotope Supply
Compare PSTV vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PSTV PLUS THERAPEUTICS Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.